Candidiasis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

  • ID: 4340317
  • Report
  • 95 pages
  • P&S Market Research
1 of 3
Disease Overview

Candidiasis is a very common type of fungal infection caused by fungus known as candida. Candida is usually found in various parts of our body including mouth, skin or belly and cause no harm. It is only when this fungus gets right environment it multiplies and grows uncontrollably. This condition results in occurring of the infection, known as candidiasis. There are various different types of candidiasis like thrush (oropharyngeal candidiasis), genital yeast infection (genital candidiasis), diaper rash from yeast infection and invasive candidiasis.

The symptoms of candidiasis include yellow or white patches on the lips, tongue, lips, roof of mouth, gums and inner cheeks, soreness in the mouth and throat, cracking at the corners of the mouth, pain during swallowing, itching in the vagina, swelling and redness of the vagina, pain, discomfort, white discharge from vagina, fever and chills. The diagnosis of candidiasis done methods such as wet mount, microscope examination, gram stain, potassium hydroxide smears, urinalysis, urine fungal cultures and endoscopy. The treatment of candidiasis includes drugs such as echinocandins, caspofungin, micafungin and anidulafungin, along with fluconazole, as well as lipid formulations of amphotericin B medications in various situations.

Pipeline Analysis

Drug manufacturing companies are in the quest to find better and new treatment strategies with potential targets such as beta-1,3-D glucan synthase and cytochrome P450 sterol 14a-demethylase (CYP51) which can also prove to be effective in candidiasis treatment. The U.S. Food and Drug Administration (USFDA) has granted various designations including orphan drug, qualified infectious disease product (QIDP) with fast track status to many drugs which are driving the growth of the pipeline.

As of May 2017, the candidiasis pipeline comprises approximately 22 active drug candidates in different stages of development.

Competitive Landscape

Some of the key players developing drugs for the treatment of candidiasis include Seren Pharmaceuticals, Inc., SCYNEXIS, Inc., Matinas Biopharma Holdings, Inc. and others.

Scope for Customization

Customization is offered as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
  • Market Forecast - Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles - Wider company coverage in terms of detailed analysis or additional company profiles
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

3. Executive Summary

4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Candidiasis Pipeline Analysis
4.4.1 Pipeline Analysis By Phase
4.4.2 Pipeline Analysis By Route Of Administration
4.4.3 Pipeline Analysis By Molecule Type
4.4.4 Pipeline Analysis By Company

5. Candidiasis Pipeline Analysis By Phase (2017)
5.1 Phase Iii: Drug Profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase Ii: Drug Profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase I: Drug Profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Clinical Trials
5.3.4 Clinical Results
5.3.5 Strategic Development
5.3.6 Designation
5.3.7 Grants
5.3.8 Patent
5.3.9 Technology
5.4 Pre-Clinical: Drug Profiles
5.4.1 Pre-Clinical Study
5.4.2 Pre-Clinical Results
5.4.3 Strategic Development
5.4.4 Designation
5.4.5 Grants
5.4.6 Patent
5.4.7 Technology
5.5 Discovery: Drug Profiles
5.5.1 Strategic Development
5.5.2 Designation
5.5.3 Grants
5.5.4 Patent

6 Competitive Landscape
6.1 Key Players Benchmarking For Candidiasis Drug Candidates
6.2 Swot Analysis Of Candidiasis Pipeline

7 Company Profiles
7.1 Business Overview
7.2 Product And Service Offerings

8 Appendix
8.1 Abbreviations

List Of Tables
Pipeline Analysis Of Candidiasis, By Company (2017)
Description Of Phase Iii Drug Candidates
Clinical Trials Of Phase Iii Drug Candidates
Description Of Phase Ii Drug Candidates
Clinical Trials Of Phase Ii Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Description Of Pre-Clinical Drug Candidates
Description Of Discovery Drug Candidates
Companies- At A Glance

List Of Figures
Research Methodology For Candidiasis Therapeutic Pipeline Analysis
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents, By Industry Participant
Breakdown Of Primary Research Respondents, By Company Type
Number Of Candidiasis Drug Candidates Under Development (2017)
Candidiasis Pipeline Split, By Route Of Administration (2017)
Candidiasis Pipeline Split, By Molecule Type (2017)
Key Players Benchmarking For Candidiasis Drug Candidates
Swot Analysis Of Candidiasis Pipeline
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown